EWTX
Edgewise Therapeutics, Inc.
Biotechnology
Market Cap$3.82B
5Y Perf.+9.5%
Compare Stocks
2 / 10Try these comparisons:
Stock Comparison
EWTX vs IMVT
Revenue, margins, valuation, and 5-year total return — side by side.
IMVT
Immunovant, Inc.
Biotechnology
Market Cap$5.53B
5Y Perf.+69.7%
EWTX vs IMVT — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | EWTX | IMVT |
|---|---|---|
| Industry | Biotechnology | Biotechnology |
| Market Cap | $3.82B | $5.53B |
| Revenue (TTM) | $0.00 | $0.00 |
| Net Income (TTM) | $-176M | $-464M |
| Total Debt | $4M | $98K |
| Cash & Equiv. | $61M | $714M |
EWTX vs IMVT — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
EWTX
IMVT
| Stock | Mar 21 | May 26 | Return |
|---|---|---|---|
| Edgewise Therapeuti… (EWTX) | 100 | 109.5 | +9.5% |
| Immunovant, Inc. (IMVT) | 100 | 169.7 | +69.7% |
Price return only. Dividends and distributions are not included.
Quick Verdict: EWTX vs IMVT
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: EWTX leads in 4 of 6 categories, making it the strongest pick for profitability and margin quality and capital preservation and lower volatility. Immunovant, Inc. is the stronger pick specifically for growth and revenue expansion. As sector peers, any of these can serve as alternatives in the same allocation.
EWTX
Edgewise Therapeutics, Inc.
The Income Pick
EWTX carries the broadest edge in this set and is the clearest fit for income & stability and growth exposure.
- beta 1.09
- EPS growth -12.4%
- Lower volatility, beta 1.09, Low D/E 0.8%, current ratio 19.85x
Best for: income & stability and growth exposure
IMVT
Immunovant, Inc.
The Long-Run Compounder
IMVT is the clearest fit if your priority is long-term compounding.
- 173.6% 10Y total return vs EWTX's 18.6%
- -21.3% revenue growth vs EWTX's -22.4%
Best for: long-term compounding
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | IMVT | -21.3% revenue growth vs EWTX's -22.4% |
| Quality / Margins | EWTX | 4.3% margin vs IMVT's 3.2% |
| Stability / Safety | EWTX | Beta 1.09 vs IMVT's 1.37 |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | EWTX | +145.0% vs IMVT's +96.1% |
| Efficiency (ROA) | EWTX | -31.0% ROA vs IMVT's -44.1% |
EWTX vs IMVT — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLEWTXLAGGINGIMVT
IMVTImmunovant, Inc.
1leads
EWTXEdgewise Therapeutics…
2leads
6 Total Categories
CATEGORYLEADERvs IMVTMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
IMVT1/1
Valuation MetricsMultiples, price ratios, and targets
Tied
—
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
EWTX4/7
Total Returns1Y, 3Y, 5Y total returns with dividends
EWTX4/6
Risk & VolatilityBeta, volatility, and downside exposure
Tied
—
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
IMVT leads this category, winning 1 of 1 comparable metric.
Income & Cash Flow (Last 12 Months)
EWTX and IMVT operate at a comparable scale, with $0 and $0 in trailing revenue.
| Metric | EWTXEdgewise Therapeu… | IMVTImmunovant, Inc. |
|---|---|---|
| RevenueTrailing 12 months | $0 | $0 |
| EBITDAEarnings before interest/tax | -$200M | -$487M |
| Net IncomeAfter-tax profit | -$176M | -$464M |
| Free Cash FlowCash after capex | -$149M | -$423M |
| Gross MarginGross profit ÷ Revenue | — | — |
| Operating MarginEBIT ÷ Revenue | — | — |
| Net MarginNet income ÷ Revenue | — | — |
| FCF MarginFCF ÷ Revenue | — | — |
| Rev. Growth (YoY)Latest quarter vs prior year | — | — |
| EPS Growth (YoY)Latest quarter vs prior year | -7.0% | +19.7% |
IMVT leads this category, winning 1 of 1 comparable metric.
Valuation Metrics
Evenly matched — EWTX and IMVT each lead in 1 of 2 comparable metrics.
Valuation Metrics
| Metric | EWTXEdgewise Therapeu… | IMVTImmunovant, Inc. |
|---|---|---|
| Market CapShares × price | $3.8B | $5.5B |
| Enterprise ValueMkt cap + debt − cash | $3.8B | $4.8B |
| Trailing P/EPrice ÷ TTM EPS | -21.83x | -9.97x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | — |
| Price / SalesMarket cap ÷ Revenue | — | — |
| Price / BookPrice ÷ Book value/share | 7.01x | 5.83x |
| Price / FCFMarket cap ÷ FCF | — | — |
Evenly matched — EWTX and IMVT each lead in 1 of 2 comparable metrics.
Profitability & Efficiency
EWTX leads this category, winning 4 of 7 comparable metrics.
Profitability & Efficiency
EWTX delivers a -32.5% return on equity — every $100 of shareholder capital generates $-33 in annual profit, vs $-47 for IMVT. IMVT carries lower financial leverage with a 0.00x debt-to-equity ratio, signaling a more conservative balance sheet compared to EWTX's 0.01x. On the Piotroski fundamental quality scale (0–9), EWTX scores 3/9 vs IMVT's 2/9, reflecting mixed financial health.
| Metric | EWTXEdgewise Therapeu… | IMVTImmunovant, Inc. |
|---|---|---|
| ROE (TTM)Return on equity | -32.5% | -47.1% |
| ROA (TTM)Return on assets | -31.0% | -44.1% |
| ROICReturn on invested capital | -32.4% | — |
| ROCEReturn on capital employed | -38.7% | -66.1% |
| Piotroski ScoreFundamental quality 0–9 | 3 | 2 |
| Debt / EquityFinancial leverage | 0.01x | 0.00x |
| Net DebtTotal debt minus cash | -$57M | -$714M |
| Cash & Equiv.Liquid assets | $61M | $714M |
| Total DebtShort + long-term debt | $4M | $98,000 |
| Interest CoverageEBIT ÷ Interest expense | — | — |
EWTX leads this category, winning 4 of 7 comparable metrics.
Total Returns (Dividends Reinvested)
EWTX leads this category, winning 4 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in IMVT five years ago would be worth $16,241 today (with dividends reinvested), compared to $12,168 for EWTX. Over the past 12 months, EWTX leads with a +145.0% total return vs IMVT's +96.1%. The 3-year compound annual growth rate (CAGR) favors EWTX at 53.3% vs IMVT's 12.1% — a key indicator of consistent wealth creation.
| Metric | EWTXEdgewise Therapeu… | IMVTImmunovant, Inc. |
|---|---|---|
| YTD ReturnYear-to-date | +49.8% | +5.1% |
| 1-Year ReturnPast 12 months | +145.0% | +96.1% |
| 3-Year ReturnCumulative with dividends | +260.1% | +40.9% |
| 5-Year ReturnCumulative with dividends | +21.7% | +62.4% |
| 10-Year ReturnCumulative with dividends | +18.6% | +173.6% |
| CAGR (3Y)Annualised 3-year return | +53.3% | +12.1% |
EWTX leads this category, winning 4 of 6 comparable metrics.
Risk & Volatility
Evenly matched — EWTX and IMVT each lead in 1 of 2 comparable metrics.
Risk & Volatility
EWTX is the less volatile stock with a 1.09 beta — it tends to amplify market swings less than IMVT's 1.37 beta. A beta below 1.0 means the stock typically moves less than the S&P 500.
| Metric | EWTXEdgewise Therapeu… | IMVTImmunovant, Inc. |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.09x | 1.37x |
| 52-Week HighHighest price in past year | $39.96 | $30.09 |
| 52-Week LowLowest price in past year | $12.15 | $13.36 |
| % of 52W HighCurrent price vs 52-week peak | +89.0% | +90.5% |
| RSI (14)Momentum oscillator 0–100 | 66.1 | 60.2 |
| Avg Volume (50D)Average daily shares traded | 919K | 1.4M |
Evenly matched — EWTX and IMVT each lead in 1 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Wall Street rates EWTX as "Buy" and IMVT as "Buy". Consensus price targets imply 67.2% upside for IMVT (target: $46) vs 8.7% for EWTX (target: $39).
| Metric | EWTXEdgewise Therapeu… | IMVTImmunovant, Inc. |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy |
| Price TargetConsensus 12-month target | $38.67 | $45.50 |
| # AnalystsCovering analysts | 9 | 23 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | — |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
EWTX leads in 2 of 6 categories (Profitability & Efficiency, Total Returns). IMVT leads in 1 (Income & Cash Flow). 2 tied.
Best OverallEdgewise Therapeutics, Inc. (EWTX)Leads 2 of 6 categories
Loading custom metrics...
EWTX vs IMVT: Frequently Asked Questions
8 questions · data-driven answers · updated daily
01Is EWTX or IMVT a better buy right now?
Analysts rate Edgewise Therapeutics, Inc.
(EWTX) a "Buy" — based on 9 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — EWTX or IMVT?
Over the past 5 years, Immunovant, Inc.
(IMVT) delivered a total return of +62. 4%, compared to +21. 7% for Edgewise Therapeutics, Inc. (EWTX). Over 10 years, the gap is even starker: IMVT returned +173. 6% versus EWTX's +18. 6%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — EWTX or IMVT?
By beta (market sensitivity over 5 years), Edgewise Therapeutics, Inc.
(EWTX) is the lower-risk stock at 1. 09β versus Immunovant, Inc. 's 1. 37β — meaning IMVT is approximately 26% more volatile than EWTX relative to the S&P 500. On balance sheet safety, Immunovant, Inc. (IMVT) carries a lower debt/equity ratio of 0% versus 1% for Edgewise Therapeutics, Inc. — giving it more financial flexibility in a downturn.
04Which is growing faster — EWTX or IMVT?
On earnings-per-share growth, the picture is similar: Edgewise Therapeutics, Inc.
grew EPS -12. 4% year-over-year, compared to -45. 2% for Immunovant, Inc.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — EWTX or IMVT?
Edgewise Therapeutics, Inc.
(EWTX) is the more profitable company, earning 0. 0% net margin versus 0. 0% for Immunovant, Inc. — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: EWTX leads at 0. 0% versus 0. 0% for IMVT. At the gross margin level — before operating expenses — EWTX leads at 0. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Which pays a better dividend — EWTX or IMVT?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
07Is EWTX or IMVT better for a retirement portfolio?
For long-horizon retirement investors, Edgewise Therapeutics, Inc.
(EWTX) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1. 09)). Both have compounded well over 10 years (EWTX: +18. 6%, IMVT: +173. 6%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
08What are the main differences between EWTX and IMVT?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.